From kinetics and cellular cooperations to cancer immunotherapies

Alain Trautmann

doi:10.18632/oncotarget.8242

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

From kinetics and cellular cooperations to cancer immunotherapies

Alain Trautmann _

PDF | HTML | How to cite

Oncotarget. 2016; 7:44779-44789. https://doi.org/10.18632/oncotarget.8242

Metrics: PDF 1997 views | HTML 1861 views | ?

Abstract

Alain Trautmann1,2,3,4

1 INSERM, U1016, Institut Cochin, Paris, France

2 CNRS, UMR8104, Paris, France

3 Université Paris Descartes, Sorbonne Paris Cité, Paris, France

4 Equipe Labellisée “Ligue contre le Cancer”, Paris, France

Correspondence to:

Alain Trautmann, email:

Keywords: immunotherapy, kinetics, cellular cooperation

Received: February 02, 2016 Accepted: March 04, 2016 Published: March 21, 2016

Abstract

In this review will be underlined two simple ideas of potential interest for the design of cancer immunotherapies. One concerns the importance of kinetics, with the key notion that a single cause may trigger two opposite effects with different kinetics. The importance of this phenomenon will be underlined in neurobiology, transcription networks and the immune system. The second idea is that efficient immune responses have been selected against pathogens, throughout evolution. They are never due to a single cell type, but always require multiple, complex cellular cooperations. One cannot recognize this fact and persist in the presently dominant T-cell centered view of cancer immunotherapies. Suggestions will be made to incorporate these simple ideas for improving these therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8242

Publication Alerts

Reviews:

From kinetics and cellular cooperations to cancer immunotherapies

Abstract